150 related articles for article (PubMed ID: 16908365)
21. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
22. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
[TBL] [Abstract][Full Text] [Related]
23. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
[TBL] [Abstract][Full Text] [Related]
24. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
25. Etanercept combined with methotrexate for high-need psoriasis.
Driessen RJ; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
[TBL] [Abstract][Full Text] [Related]
26. Etanercept: efficacy and safety.
Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
[TBL] [Abstract][Full Text] [Related]
27. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
Koc E; Tunca M; Akgul EO; Akar A; Kurt Y; Kurumlu Z; Erbil K; Kilic S
J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
Papp KA; Poulin Y; Bissonnette R; Bourcier M; Toth D; Rosoph L; Poulin-Costello M; Setterfield M; Syrotuik J
J Am Acad Dermatol; 2012 Feb; 66(2):e33-45. PubMed ID: 20850895
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
[TBL] [Abstract][Full Text] [Related]
30. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E
Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936
[TBL] [Abstract][Full Text] [Related]
31. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
[TBL] [Abstract][Full Text] [Related]
32. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Stramazzotti D; Morichetti D; Bernardini ML; Mannello B; Fabris G; Offidani A
Br J Dermatol; 2007 Dec; 157(6):1155-60. PubMed ID: 17916208
[TBL] [Abstract][Full Text] [Related]
33. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
Carlin CS; Feldman SR; Krueger JG; Menter A; Krueger GG
J Am Acad Dermatol; 2004 Jun; 50(6):859-66. PubMed ID: 15153885
[TBL] [Abstract][Full Text] [Related]
34. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
35. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
Gordon KB; Gottlieb AB; Leonardi CL; Elewski BE; Wang A; Jahreis A; Zitnik R
J Dermatolog Treat; 2006; 17(1):9-17. PubMed ID: 16467018
[TBL] [Abstract][Full Text] [Related]
36. Etanercept and psoriasis, from clinical studies to real life.
Jacob SE; Sergay A; Kerdel FA
Int J Dermatol; 2005 Aug; 44(8):688-91. PubMed ID: 16101875
[TBL] [Abstract][Full Text] [Related]
37. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
38. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
39. Etanercept in the treatment of palmoplantar pustulosis.
Bissonnette R; Poulin Y; Bolduc C; Maari C; Provost N; Syrotuik J; Poulin-Costello CM; Nigen S
J Drugs Dermatol; 2008 Oct; 7(10):940-6. PubMed ID: 19112757
[TBL] [Abstract][Full Text] [Related]
40. Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis.
Hutmacher MM; Nestorov I; Ludden T; Zitnik R; Banfield C
J Clin Pharmacol; 2007 Feb; 47(2):238-48. PubMed ID: 17244775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]